Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Am J Physiol Regul Integr Comp Physiol (2010) 299:R94552
Amitani, M., Asakawa, A., Amitani, H
as Januvia) Vildagliptin [7] (EU approved in 2007, and marketed in the EU by Novartis as Galvus) Saxagliptin (FDA approved in 2009, and marketed as Onglyza) Linagliptin (FDA approved in 2011, and marketed as Tradjenta by Eli Lilly and Company and Boehringer Ingelheim) [8] Gemigliptin (approved in Korea in 2012, and marketed by LG Life Sciences as Zemiglo, among other names) [9] Anagliptin (approved in Japan as Suiny in 2012
Heitmann BL
Although the Melonnpan pipeline is based on highly trained and validated data sets, and its predictions are based on the actual microbial functional potential observed in the samples, it is important to note that the metabolites described hereafter are predicted (i.e., not derived from targeted/untargeted metabolomic analysis)
US$ 20.91
US$ 24.44
US$ 27.95
